Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.339 – $0.394
Volume211,915
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.3M
Price / earnings
—
Price / book
0.05×
Price / sales
0.51×
EV / sales
0.13×
EV / EBITDA
-0.08×
Profitability
Earnings per share
-$1.26
Return on assets
-15.75%
Return on equity
-16.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
22.2×
Quick ratio
22.2×
Cash ratio
0.87×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EVGN, quarterly periods
Line item
Q1 FY2016 Mar 31, 2016
Q4 FY2015 Dec 31, 2015
Q3 FY2015 Sep 30, 2015
Q2 FY2015 Jun 30, 2015
Q1 FY2015 Mar 31, 2015
Q4 FY2014 Dec 31, 2014
Q3 FY2014 Sep 30, 2014
Q2 FY2014 Jun 30, 2014
Revenue
$2.02M
$2.46M
$3.31M
$2.66M
$2.7M
$3.64M
$3.16M
$3.85M
Cost of revenue
$1.52M
$2.01M
$2.49M
$1.93M
$1.83M
$2.38M
$2.34M
$2.43M
Gross profit
$501K
$457K
$822K
$724K
$871K
$1.26M
$827K
$1.43M
Selling, general and administrative
$998K
$1.24M
$1M
$1.17M
$963K
$1.08M
$984K
$1.24M
Research and development
$4.09M
$4.58M
$3.6M
$4.19M
$4.04M
$4.78M
$4.15M
$3.92M
Total operating expenses
$5.09M
$5.83M
$4.6M
$5.37M
$5M
$5.85M
$5.13M
$5.15M
Operating income
-$4.58M
-$5.37M
-$3.78M
-$4.64M
-$4.13M
-$4.6M
-$4.31M
-$3.73M
Interest expense
-$122K
-$629K
-$368K
-$639K
-$227K
-$488K
-$500K
-$166K
Income before taxes
-$3.37M
-$5.47M
-$3.38M
-$4.95M
-$3.41M
-$4.82M
-$4.18M
-$3.19M
Income taxes
—
—
—
—
—
—
—
—
Net income
-$3.37M
-$5.47M
-$3.38M
-$4.95M
-$3.41M
-$4.82M
-$4.18M
-$3.19M
Net income attributable to common shareholders
-$3.37M
-$5.47M
-$3.38M
-$4.95M
-$3.41M
-$4.82M
-$4.18M
-$3.19M
EBITDA
-$3.99M
-$5.37M
-$3.2M
-$4.03M
-$3.47M
-$4.6M
-$3.75M
-$3.19M
Basic earnings per share
-$1.30
-$2.20
-$1.30
-$2.00
-$1.30
-$1.90
-$1.70
-$1.30
Diluted earnings per share
-$1.30
-$2.20
-$1.30
-$2.00
-$1.30
-$1.90
-$1.70
-$1.30
Recent news
Company coverage with links to the original publishers.
The plant genotyping equipment market is experiencing significant growth due to advancements in sequencing technologies and increasing demand for high-yield, stress-tolerant crops. The market is expected to reach $1662.43 million by 2032, driven by the need for efficient, high-yield crop production methods.
The global agricultural biotechnology market is expected to grow from USD 121.24 billion in 2023 to USD 268.32 billion by 2033, driven by increasing demand for sustainable agriculture and food security.
Evogene (EVGN) delivered earnings and revenue surprises of 7.14% and 66.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.